Laurent Pharmaceuticals extends COVID-19 Phase 2 study with oral antiviral LAU-7b that has showed 100% reduction in the risk of progression onto mechanical ventilation and death

15 December 2021

FDA allows Phase 2 study extension focusing on moderate-to-severe COVID-19 patients and grants Type B meeting to discuss eligibility to Emergency...

Read More

Laurent Pharmaceuticals Announces Topline Results from its Phase 2 RESOLUTION Clinical Trial of LAU-7b for the Treatment of COVID-19

30 September 2021

Laurent Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing LAU-7b, a first-in-class pro-resolving drug candidate, reported today topline results from its Phase...

Read More


Laurent Pharma to participate to BIO International Convention, June 5-8, 2023, Boston, MA

Laurent Pharma to participate to BIO International Convention, June 13-16, 2022 – San Diego, CA
Laurent Pharma to participate to BIO-Europe Spring, March 28-31, 2022
Laurent Pharma to participate to BiotechGate, February 7-9, 2022
Laurent Pharma to participate to Biotech Showcase, January 9-11 and 17-19, 2022
Laurent Pharma to participate to H.C. Wainwright 23rd Annual Global Investment Conference,
September 13-15, 2021